Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GEN1286 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GEN1286 | DRUG | Specified dose on specified days. |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GEN1286 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in clinical development and has not been approved by regulatory authorities. The drug is being studied in a Phase 1/2 clinical trial to evaluate its safety and efficacy in patients with advanced solid tumors.
GEN1286 is being developed by Genmab A/S, a biotechnology company listed on the Nasdaq under the ticker symbol GMAB. Genmab is conducting clinical trials to evaluate the drug's potential in treating advanced solid tumors.
GEN1286 is currently in Phase 2 clinical development. The ongoing study is a Phase 1/2 trial, and the drug is still investigational, meaning it has not been approved by the FDA or other regulatory bodies. The trial is active but not recruiting participants.
GEN1286 is being studied in a single clinical trial with the identifier NCT06685068, titled "A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors." The trial is currently active but not recruiting, with an enrollment of 23 patients.
No alternative names for GEN1286 have been identified. The drug is solely referred to as GEN1286 in clinical trial records and by its developer, Genmab A/S. It is a distinct investigational compound being studied for advanced solid tumors.